Evonik Rejects BASF's €10.3 Billion Opening Salvo as RAG-Stiftung Emerges as Kingmaker
Published on 09/29/2026 at 07:40 | Editorial boerse-global.de
BASF's surprise approach to Evonik has jolted Germany's chemicals sector out of its long slumber — but the Ludwigshafen giant's first move fell flat in Essen. According to reports from Handelsblatt, Reuters and the Financial Times on Monday, Evonik turned down an unsolicited takeover proposal valuing the specialty chemicals maker at roughly €10.3 billion in equity, or about €22.15 per share. Including debt, the total package would have been worth some €14 billion.
That equated to a premium of just over 28% to Evonik's price before the first market chatter surfaced. It wasn't enough. Evonik's leadership deemed the figure too low to justify formal talks or a look at the books, and BASF was denied due diligence access. Still, BASF has confirmed official exploratory discussions, even as it stresses the outcome remains wide open.
A Shift in the Investment Case
The stock's reaction tells its own story. Evonik shares closed Monday at €19.88, hovering just beneath their 52-week high of €20.00, after trading at €19.79 with a 1.8% daily gain earlier in the session. For investors, the narrative has flipped: what was once a wager on a sluggish industry recovery has become an M&A poker game.
The decisive card belongs to the RAG-Stiftung, which holds close to 44% of Evonik's equity. No control change — and certainly no full integration — can happen without the foundation's blessing. Its response to Essen's hard line will be the next real test for the market.
Labor's voice carries weight too. Michael Vassiliadis, head of the IGBCE union, struck a skeptical tone on Monday, cautioning that sheer size does not automatically protect jobs and demanding binding investment commitments for sites and workers. With both companies already running their own cost-cutting programs — Evonik recently announced 3,200 job cuts between 2027 and 2029 — the political temperature is rising. Absent credible guarantees from BASF, the door to further engagement could slam shut.
Should investors sell immediately? Or is it worth buying Evonik?
Where the Value Case Lives
If the two sides do find common ground, shareholders stand to capture a meaningful re-rating. Deutsche Bank analysts note that the overlap spans roughly a third of BASF's revenue and about two-thirds of Evonik's business, pointing to substantial savings in administration, procurement and logistics. Analyst Virginie Boucher-Ferte of Deutsche Bank Research put it bluntly after news of the talks broke: the genie is out of the bottle. Should BASF need to raise its bid in earnest, market participants are eyeing a €25-per-share threshold.
Bernstein's James Hooper observed that the raw numbers of such a combination look attractive, even if execution is complex. Baader Europe sees clear synergies — in isocyanates such as MDI and TDI, in catalysts and surfactants, and through pairing BASF's vitamins division with Evonik's methionine business. A sweetened offer along those lines could lift the stock step by step toward €25, swiftly erasing valuation discounts. Should the RAG-Stiftung signal openness above a certain price, trading would gain fresh momentum.
BASF has financial room to maneuver after selling its coatings business, and the official rebuff could draw other suitors into the fray. As long as a bidding contest or an improved offer remains on the table, the shares have solid downside support.
The Bear Case: Back to Fundamentals
A definitive BASF retreat would bring a rude awakening. Stripped of takeover appeal, Evonik would face Europe's chemicals crisis alone. Consultancy Roland Berger estimates that nearly a tenth of European chemical production capacity is slated for closure amid weak demand and Chinese competition. Medium-term earnings prospects are dimming as well: Visible Alpha forecasts suggest Evonik's operating profit in 2030 could fall below the level expected for the current year.
Fragmentation risk compounds the picture. Should BASF pivot to alternative targets such as Lanxess, Arkema or Syensqo, the takeover premium in Evonik's stock would evaporate quickly. At a market capitalization of €9.10 billion, the shares already price in considerable deal hopes that would need to be corrected if talks collapse.
Regulatory hurdles loom, too. Baader Europe has flagged potential antitrust concerns, particularly in ingredients for personal care products. Forced divestitures of profitable units under regulatory pressure would erode the transaction's economic appeal. And with Evonik having spurned the first approach so brusquely, an abrupt end to the sondierungsgespräche is a live possibility — one that would send short-term arbitrage investors heading for the exits and likely drag the stock back toward pre-talk levels.
What to Watch
For now, the tactical picture hinges on a handful of signals. So long as the price stays within striking distance of its recent peak, the market is pricing in a continuation of the standoff. A raised bid from BASF or a signal of willingness from the RAG-Stiftung would put quotes beyond the current €22.15 offer within reach. A final rejection from Ludwigshafen, by contrast, would likely trigger profit-taking.
The immediate catalyst is how the RAG-Stiftung responds to Essen's refusal to engage. If the foundation backs management's hard line without leaving room for renegotiation, attention will swing back entirely to Evonik's internal cost-cutting plans through 2029. Should BASF instead push toward a formal takeover offer, or let the talks fizzle without any narrowing of positions, the market will read either outcome as the starting gun for the next phase.
Ad
Evonik Stock: New Analysis - 29 September
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
